These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 26438328)

  • 1. Diabetic nephropathy: What does the future hold?
    Montero RM; Covic A; Gnudi L; Goldsmith D
    Int Urol Nephrol; 2016 Jan; 48(1):99-113. PubMed ID: 26438328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.
    Schjoedt KJ; Jacobsen P; Rossing K; Boomsma F; Parving HH
    Horm Metab Res; 2005 Apr; 37 Suppl 1():4-8. PubMed ID: 15918104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of diabetic nephropathy: Recent progress and future perspective.
    Ahmad J
    Diabetes Metab Syndr; 2015; 9(4):343-58. PubMed ID: 25845297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of nephropathy in patients with type 2 diabetes.
    Critchley JA; Zhao HL; Tomlinson B; Leung W; Thomas GN; Chan JC; Cockram CS
    Chin Med J (Engl); 2002 Jan; 115(1):129-35. PubMed ID: 11930647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renin Angiotensin Aldosterone System (RAAS): its biology and drug targets for treating diabetic nephropathy.
    Zain M; Awan FR
    Pak J Pharm Sci; 2014 Sep; 27(5):1379-91. PubMed ID: 25176370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
    de Zeeuw D
    Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update on the management of nephropathy in type 2 diabetes.
    Zhao HL; Thomas GN; Leung W; Tomlinson B; Hsu YH; Chan P
    J Chin Med Assoc; 2003 Nov; 66(11):627-36. PubMed ID: 14768849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current concepts in the management of diabetic nephropathy.
    Waanders F; Visser FW; Gans RO
    Neth J Med; 2013 Nov; 71(9):448-58. PubMed ID: 24218418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving microvascular outcomes in patients with diabetes through management of hypertension.
    McGill JB
    Postgrad Med; 2009 Mar; 121(2):89-101. PubMed ID: 19332966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging therapeutic strategies in diabetic nephropathy.
    Ravera M; Re M; Weiss U; Deferrari L; Deferrari G
    J Nephrol; 2007; 20 Suppl 12():S23-32. PubMed ID: 18050139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The renin-angiotensin-aldosterone system and its blockade in diabetic nephropathy: main focus on the role of aldosterone.
    Schjoedt KJ
    Dan Med Bull; 2011 Apr; 58(4):B4265. PubMed ID: 21466768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel effective drugs for diabetic kidney disease? or not?
    Gentile G; Mastroluca D; Ruggenenti P; Remuzzi G
    Expert Opin Emerg Drugs; 2014 Dec; 19(4):571-601. PubMed ID: 25376947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetic nephropathy -- a multifaceted target of new therapies.
    Choudhury D; Tuncel M; Levi M
    Discov Med; 2010 Nov; 10(54):406-15. PubMed ID: 21122472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.
    Jacobsen P; Andersen S; Rossing K; Jensen BR; Parving HH
    Kidney Int; 2003 May; 63(5):1874-80. PubMed ID: 12675866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnosis and management of diabetic nephropathy].
    Kitada M; Koya D
    Nihon Rinsho; 2015 Dec; 73(12):2037-43. PubMed ID: 26666150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Role of the renin-angiotensin system in the pathogenesis, clinical picture and treatment of diabetic nephropathy].
    Wittmann I; Degrell P; Komáromy A; Molnár GA; Wagner Z; Wagner L; Mazák I; Nagy J
    Orv Hetil; 2003 Mar; 144(13):613-9. PubMed ID: 12728786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteinuria-lowering effect of heparin therapy in diabetic nephropathy without affecting the renin-angiotensin-aldosterone system.
    Benck U; Haeckel S; Clorius JH; van der Woude FJ
    Clin J Am Soc Nephrol; 2007 Jan; 2(1):58-67. PubMed ID: 17699388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deletion insertion polymorphism of the angiotensin converting enzyme gene and progression of diabetic nephropathy.
    Björck S; Blohmé G; Sylvén C; Mulec H
    Nephrol Dial Transplant; 1997; 12 Suppl 2():67-70. PubMed ID: 9269704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aliskiren reduces morning blood pressure in hypertensive patients with diabetic nephropathy.
    Takenaka T; Nobe K; Okayama M; Kojima E; Nodaira Y; Sueyoshi K; Hoshi H; Watanabe Y; Takane H; Suzuki H
    Clin Exp Hypertens; 2012; 34(4):243-8. PubMed ID: 22559034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.